Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still ’s Disease

ConclusionsOur findings suggest that baricitinib therapy could provide rapid and durable clinical and laboratory improvement in patients with refractory AOSD. Treatment seemed to be well tolerated by these patients. The long-term efficacy and safety of baricitinib therapy for AOSD should be assessed further in prospective controlled clinical trials in the future.Trial RegistrationTrial registration number (TRN): ChiCTR2200061599. Date of registration: 29 June 2022 (retrospectively registered).
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research